<DOC>
	<DOCNO>NCT00827034</DOCNO>
	<brief_summary>This study evaluate potential drug-drug interaction Dimebon FDA-recommended CYP2C9 substrate warfarin healthy subject . Conformance guidance include general study design use randomize , open label , single-dose warfarin , steady-state Dimebon , 2-sequence , 2-treatment , 2-period crossover design minimum 7-day washout period treatment .</brief_summary>
	<brief_title>A Phase 1 , Randomized , Open-Label , Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon ( PF 01913539 ) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Healthy male and/or female ( nonchildbearing potential ) subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Prothrombin time ( PT ) /INR , partial thromboplastin time ( PTT ) . Plasma Protein C Protein S activity ( functional ) within normal reference range . A known sensitivity previous intolerance Dimebon warfarin . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding Screening . Subjects receive warfarin treatment active thromboembolic event ( ie , pulmonary embolism , deep vein thrombosis ) , well subject anticoagulated prosthetic heart valve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Dimebon Warfarin Drug-Drug Interaction</keyword>
</DOC>